1067892-47-0

Basic information

• Product Name: Wortmannin-Rapamycin Conjugate
• Synonyms: Wortmannin-Rapamycin Conjugate;ATASUAOFUAOSAN-NVEIXTJJSA-N
• CAS NO: 1067892-47-0
• Molecular Formula: C88H131N3O23
• Molecular Weight: 1598.98804
• Mol File: 1067892-47-0.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Wortmannin-Rapamycin Conjugate(CAS DataBase Reference)
• NIST Chemistry Reference: Wortmannin-Rapamycin Conjugate(1067892-47-0)
• EPA Substance Registry System: Wortmannin-Rapamycin Conjugate(1067892-47-0)

Safety Data

• Hazardous Substances Data: 1067892-47-0(Hazardous Substances Data)

Usage

Description

Wortmannin-Rapamycin Conjugate is a combination of two potent inhibitors, Wortmannin and Rapamycin, which are conjugated via a prodrug linker. Wortmannin is a potent inhibitor of Phosphoinositide 3-kinase (PI3K) enzymes, while Rapamycin blocks mTOR Complex 1 (TORC1). The conjugate is designed to target and inhibit the synergistic actions of PI3K and mTOR pathways, which are known to promote cancer growth. Upon hydrolysis of the prodrug linker in vivo, the inhibitors are released, providing a more effective approach to cancer treatment.

Uses

Used in Oncology:
Wortmannin-Rapamycin Conjugate is used as an anticancer agent for the treatment of various types of tumors. It is particularly effective in inhibiting the growth of HT-29 colon tumors and A498 renal tumors in mice, showing better results than Rapamycin alone. The conjugate targets the PI3K and mTOR pathways, which are crucial for cancer promotion, and its hydrolysis in vivo releases the inhibitors for a more potent effect.
Used in Combination Therapy:
Wortmannin-Rapamycin Conjugate is used in combination with other therapeutic agents, such as the VEGF-blocker Bevacizumab, to enhance the treatment of larger A498 tumors. This combination therapy results in substantial tumor regression, demonstrating the potential of the conjugate to improve the efficacy of existing cancer treatments.
Used in Cancer Treatment Research:
The Wortmannin-Rapamycin Conjugate is also used as a research tool to study the effects of inhibiting the PI3K and mTOR pathways in cancer cells. Its development and application provide valuable insights into the potential of prodrug conjugates for targeted cancer therapy and the synergistic actions of different inhibitors in combating cancer growth.
Used in Drug Delivery Systems:
The Wortmannin-Rapamycin Conjugate is used to explore novel drug delivery systems that can improve the bioavailability, delivery, and therapeutic outcomes of the inhibitors. The prodrug linker allows for controlled release of the active compounds in vivo, which can potentially enhance the effectiveness and tolerability of the treatment.
Overall, the Wortmannin-Rapamycin Conjugate is a promising anticancer agent with applications in oncology, combination therapy, cancer treatment research, and drug delivery systems. Its unique design and mechanism of action offer new possibilities for the development of more effective and targeted cancer therapies.